ClinicalTrials.gg
Enrolling by invitationNCT07023965Updated Jul 11, 2025

Follow-up Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-L)

An observational study in Peripheral Arterial Disease(PAD), Arterial Occlusive Disease and Arteriosclerosis Obliterans, sponsored by Beijing Northland Biotech. Co., Ltd.. Enrolling by invitation at 5 sites in China. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-07-11.

Primary conditionChronic Limb-Threatening IschemiaRegistry: Peripheral Arterial DiseaseReclassifiedWhy we changed it
Registry
Peripheral Arterial Disease — the first condition term the registry derived for this study.
ClinicalTrials.gg
Chronic Limb-Threatening Ischemia
Why
  1. The study's listed conditions name Chronic Limb-Threatening Ischemia, a narrower term within Peripheral Arterial Disease.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Beijing Northland Biotech. Co., Ltd. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
542
Ages
20 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Chronic Limb-Threatening Ischemia with a site in China — 7 open to participants now, 7 under way, none of them phase 3. Chronic Limb-Threatening Ischemia · China.

Started
2025
with 1 other
Observational
8 of 23
5 open now
Registered
22nd of 23
by date
Lead sponsor
4 of 23
Beijing Northland Biotech. Co., Ltd.

Among the 23 studies in Chronic Limb-Threatening Ischemia with a site in China, this one is one of 2 that started in 2025, is one of 8 observational ones, and was the 22nd registered.

Chronic Limb-Threatening Ischemia

359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

Browse Chronic Limb-Threatening Ischemia studies →

Open to participants now

7 of the 23 studies in Chronic Limb-Threatening Ischemia with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 20 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Chronic Limb-Threatening Ischemia with a site in China, or all of them as a file.
02

Study summary

The goal of this observational study is to learn about the long-term effects of Donaperminogene Seltoplasmid Injection (NL003) in participants who have been received drug NL003 or placebo at least one dose from the parent phase III clinical study to treat their critical limb ischemia (CLI). The main questions it aims to answer are:

  • First, what medical problems do participants have after taking drug NL003 to treat CLI?
  • Second, does drug NL003 make CLI participants live longer without serious problems (amputations or target vessel revascularizations) ?

Participants who have already received drug NL003 for CLI will complete online surveys about their health conditions. This study will continue until at least 36 months after the participant's first dose.

Read the detailed description

This study is a multicenter, open-label, long-term follow-up cohort study. A remote follow-up system is recommended as a tool for the study, however, in-person visits or phone calls at the research center will be conducted if remote follow-up is not feasible. The study will retrospectively collect data from the last visit in the parent Phase III study and prospectively gather data following informed consent. It will continue until at least 36 months after the first dose administered to the last enrolled participant.

03

Conditions studied

  • Peripheral Arterial Disease(PAD)
  • Arterial Occlusive Disease
  • Arteriosclerosis Obliterans
  • Thromboangiitis Obliterans
  • Diabetic Foot Ulcer (DFU)
  • Diabetic Foot Ulcer Ischemic
  • Critical Limb Ischemia (CLI)

Keywords

  • HGF
  • Critical Limb Ischemia
  • Gene therapy
04

In context

Chronic Limb-Threatening Ischemia Reclassified

359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

This study's planned enrollment of 542 is above the median of 111 across 104 observational studies indexed under Chronic Limb-Threatening Ischemia.

Browse Chronic Limb-Threatening Ischemia studies →

Lead sponsor

Beijing Northland Biotech. Co., Ltd. is the lead sponsor of 11 studies on the registry; 3 are open to participants now.

Compared within Chronic Limb-Threatening Ischemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Peripheral Arterial Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
20 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants were enrolled from the parent phase III clinical study identified by protocol numbers NCT04274049 and NCT04275323.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who have previously enrolled in Phase III clinical trials of recombinant human hepatocyte growth factor plasmid injection (Donaperminogene Seltoplasmid Injection) for the treatment of critical limb ischemia (including ulcers and rest pain) and have received at least one dose of the treatment.

Exclusion criteria

Exclusion Criteria:

  • Participants who refused to provide written ;
  • Participants who refused to cooperate with the retrospective or prospective data collection.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
542 participants (estimated)
Patient registry
No

Groups and cohorts

  • Participants exposed to drug NL003 from Phase III Clinical Trials

    Drug: NL003

  • Participants exposed to placebo from Phase III Clinical Trials

    Drug: Placebo

Interventions

  • DrugNL003

    This is an observational study, and the interventions have already been administered in the preceding Phase III clinical trials.

  • DrugPlacebo

    This is an observational study, and the interventions have already been administered in the preceding Phase III clinical trials.

07

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs) and serious adverse events (SAEs)

    Time frame: Every 3±1 months after enrollment, continuing until at least 36 months after the first dose

  2. Incidence of benign and malignant tumors

    Time frame: Every 3±1 months after enrollment, continuing until at least 36 months after the first dose

  3. Incidence of significant vision loss, blindness, or other obvious visual abnormalities

    Time frame: Every 3±1 months after enrollment, continuing until at least 36 months after the first dose

  4. Incidence of major cardiovascular and cerebrovascular events

    Time frame: Every 3±1 months after enrollment, continuing until at least 36 months after the first dose

  5. Pregnancy status and its outcomes

    Time frame: Every 3±1 months after enrollment, continuing until at least 36 months after the first dose

  6. Amputation-free survival of the trial limb

    Amputation-free survival of the trial limb is one of the key endpoints for efficacy assessment. The time from the first dose administration to the occurrence of amputation above the ankle of the trial limb or death due to any cause, whichever occurs first.

    Time frame: Every 3±1 months after enrollment, continuing until at least 36 months after the first dose

  7. Amputation-free survival or target vessel revascularization composite endpoint

    Amputation-free survival or target vessel revascularization composite endpoint is one of the key endpoints for efficacy assessment. The time from the first dose administration to the occurrence of amputation above the ankle of the trial limb, death due to any cause, or target vessel revascularization\* of the trial limb, whichever occurs first.\*Target vessel revascularization: bypass grafting, endovascular revascularization, thrombectomy, or thrombolysis of the trial limb.

    Time frame: Every 3±1 months after enrollment, continuing until at least 36 months after the first dose

  8. Amputation-free survival or target vessel revascularization or neovascularization therapies (including stem cell or gene therapy) composite endpoint

    Amputation-free survival or target vessel revascularization or neovascularization therapies (including stem cell or gene therapy) composite endpoint is one of the key endpoints for efficacy assessment. The time from the first dose administration to the occurrence of amputation above the ankle of the trial limb, death due to any cause, or target vessel revascularization and neovascularization therapies (including stem cell or gene therapy) of the trial limb, whichever occurs first.

    Time frame: Every 3±1 months after enrollment, continuing until at least 36 months after the first dose

Secondary outcomes

  1. All-cause mortality rate, time to death

    Time frame: Every 3±1 months after enrollment, continuing until at least 36 months after the first dose

  2. Major amputation rate of the trial limb (amputation plane above the ankle)

    Time frame: Every 3±1 months after enrollment, continuing until at least 36 months after the first dose

  3. Minor amputation rate of the trial limb (below the ankle, including toe amputation)

    Time frame: Every 3±1 months after enrollment, continuing until at least 36 months after the first dose

  4. Incidence of target vessel revascularization of the trial limb

    Time frame: Every 3±1 months after enrollment, continuing until at least 36 months after the first dose

  5. Rehospitalization rate for worsening ischemic symptoms of the trial limb

    Time frame: Every 3±1 months after enrollment, continuing until at least 36 months after the first dose

  6. Incidence of death due to acute myocardial infarction or stroke

    Time frame: Every 3±1 months after enrollment, continuing until at least 36 months after the first dose

  7. Time to amputation of the trial limb

    Time frame: Every 3±1 months after enrollment, continuing until at least 36 months after the first dose

  8. Level of amputation of the trial limb (above the knee, knee-ankle amputation, below the ankle amputation/toe amputation)

    Time frame: Every 3±1 months after enrollment, continuing until at least 36 months after the first dose

  9. Change in Rutherford classification of the trial limb compared to baseline at first dose

    The Rutherford classification is a standardized system used to assess the severity of peripheral arterial disease (PAD) in the trial limb. It ranges from category 0 (asymptomatic) to category 6 (ischemic rest pain with gangrene). Higher categories indicate more severe disease. The change in Rutherford classification will be measured by comparing the classification at the first dose to the baseline classification.

    Time frame: Every 3±1 months after enrollment, continuing until at least 36 months after the first dose

  10. Change in rest pain of the trial limb assessed by Numeric Rating Scale (NRS) compared to baseline at first dose

    The NRS is a pain assessment tool that ranges from 0 to 10, where 0 indicates no pain and 10 indicates the worst possible pain. A higher score on the NRS indicates worse pain. The change in rest pain will be determined by comparing the NRS score at the first dose to the baseline NRS score.

    Time frame: Every 3±1 months after enrollment, continuing until at least 36 months after the first dose

  11. Change in ulceration/necrosis of the trial limb compared to baseline at first dose

    Time frame: Every 3±1 months after enrollment, continuing until at least 36 months after the first dose

08

Study locations

5 sites
09

References and documents

Related links

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2025; primary completion for Dec 2027, 30 months later.

Of 53 observational studies under Chronic Limb-Threatening Ischemia, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 59. This study's planned 30 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2025
First posted
Jun 17, 2025
StartEst.
Jun 30, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Jul 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07023965
Lead sponsor
Beijing Northland Biotech. Co., Ltd.
Responsible party
Sponsor
First posted
Jun 17, 2025
Start date
Jun 30, 2025 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jul 11, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion